ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC

The objective of this randomized controlled clinical trial is to evaluate the efficacy of ctDNA-guided rechallenge with cetuximab plus trifluridine/tipiracil compared with bevacizumab plus trifluridine/tipiracil in patients with treatment-refractory, RAS/BRAF wild-type metastatic colorectal cancer.

Trial Details

NCT ID
NCT07012954
Phase
PHASE1 / PHASE2
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Cetuximab (Erbitux, C225)
  • trifluridine/tipiracil
  • Bevacizumab ( Avastin)
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Histologically confirmed colorectal adenocarcinoma
  • Initial RAS/BRAF wild-type status
  • Received first-line treatment with FOLFOX, FOLFIRI, or FOLFOXIRI combined with cetuximab, with documented clinical benefit (CR/PR/SD) and progressi…
  • Disease progression occurred during or within 3 months after cetuximab-based first-line therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →